In a blow to Allergan (AGN), a federal judge invalidated the patents on its Restasis eye treatment, the latest twist in a captivating controversy over the fate of the best-selling medicine.

The ruling brings some of the largest generic drug makers — Mylan and Teva Pharmaceuticals (TEVA) — a big step closer to selling lower-cost versions of a product that generated nearly $1.5 billion in sales last year. For now, though, the companies must first win regulatory approval and, meanwhile, battle in court still more since Allergan plans to appeal. And this will take months to resolve, stretching well into next year.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I have been consorting with the denizens of Big Pharma long enough to sniff out this odoriferous strategy. It is essentially similar to what my marketing colleagues do when the put out ads knowingly containing violative material. They know that it will take FDA at least six months to nail them and they can jack the sales until they get nailed.

    Same deal here. Allergan knew ahead of time the odds were not in their favor, but given the slow grinding the legal system they will probably hoist the price of Restasis and jack another year’s sales before they have to take their toys home.

    Brothers and sisters: whether it’s shenanigans by pharma Marketeers or pharma company lawyers, it’s all the same game, called WHACK-A-MOLE, and one of the reasons, among many that this industry, which I was once proud to be a part of has tossed its reputation down the sh**ter.

Your daily dose of news in health and medicine

Privacy Policy